A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy

Kenji Kawada, Hironobu Minami, Keniichi Okabe, Toru Watanabe, Keniichi Inoue, Morio Sawamura, Yasuo Yagi, Tsuneo Sasaki, Shingemitsu Takashima

Research output: Contribution to journalArticlepeer-review

29 Citations (Scopus)

Abstract

Background: Hypercalcemia of malignancy is a serious complication of cancer. The objective of this study was to investigate the efficacy and safety of zoledronic acid, a new-generation bisphosphonate and the most potent inhibitor of bone resorption identified to date, for hypercalcemia of malignancy in Japanese patients. Methods: Patients with hypercalcemia of malignancy, defined as an albumin-corrected serum calcium level ≥12.0 mg/dl, were treated with a single dose of zoledronic acid, 4 mg, by 15 min infusion. Clinical end-points included the proportion of patients with complete response, which was defined as a decrease of corrected serum calcium ≤10.8 mg/dl by day 10, and time to relapse, which is defined as the duration in days between the date of infusion and last available corrected serum calcium <11.6 mg/dl. Results: Twenty-seven patients were enrolled in this study and 25 patients were evaluable for the efficacy of zoledronic acid. The mean corrected serum calcium level decreased from 14.5 to 9.6 mg/dl by day 10. The complete response rate was 84%. The median time to relapse was 23 days, ranging from 0 to 56 days. The most frequently observed adverse event was fever (≤38°C). Electrolyte abnormalities suspected to be drug related including grade 3 or 4 hypocalcemia, hypophosphatemia and hypokalemia were observed in 11 patients; however, all patients were asymptomatic. No serious adverse events associated with renal toxicity were reported. Conclusions: Zoledronic acid is well tolerated and is effective for hypercalcemia of malignancy in Japanese patients.

Original languageEnglish
Pages (from-to)28-33
Number of pages6
JournalJapanese journal of clinical oncology
Volume35
Issue number1
DOIs
Publication statusPublished - 2005
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint

Dive into the research topics of 'A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy'. Together they form a unique fingerprint.

Cite this